Elitacos™-LI

Elitacos™ LI与肝脏健康

肝脏损伤具有渐进性，从脂肪肝、肝炎、肝硬化到肝癌逐步发展，部分损伤不可逆转，并可能引发全身多系统损害。
日常生活中，酗酒、乱用药 / 吃不明保健品、长期高油高糖饮食致肥胖、熬夜劳累、误食霉变食物，是引发肝损伤的主要因素。

Elitacos™ LI 针对不同阶段的肝损伤提供多通路保护

适用于脂肪肝、肝炎、代谢相关脂肪肝病（MASLD）及肥胖相关肝损伤的预防与辅助干预。
其核心机制为：
· 抗氧化与抗炎
· 调节脂代谢
· 肠-肝轴调控

Elitacos™ LI 对急性肝损伤的保护

实验研究表明：
· Elitacos™ LI显著降低血清ALT、AST，减轻肝组织氧化损伤与病理改变。^1,2,3
· Elitacos™ LI 显著改善肝脏组织病理学与肝功能指标。^1,2

Elitacos™ LI在其他方面还有广泛应用方向与使用场景

· 预防脂肪肝、肥胖及代谢综合征。^4,5,6
· 配合降脂、护肝药物使用，改善肝功能指标。^5,6,7
· 适用于肝功能异常、高血脂、糖尿病等代谢紊乱人群，作为营养干预组成部分。^4,5,8

Elitacos™ LI的产品特点

· 来源纯净

· 来自无污染海域

· 工艺优化

· 产品在气味、色泽、流散性上表现更佳，口感温和，安全可靠

· 应用产品

· 饮料、固体饮料、乳制品及保健品剂型、肉制品、烘焙食品等

· 技术依托

· 采用中国科学院过程工程研究所酶法定向降解技术，活性更高, 靶向应用效果好

参考文献
1. Zhang, H., et al. (2021). Hepatoprotective effect of chito-oligosaccharides against CCl₄-induced acute liver injury in mice: Role of antioxidant and anti-apoptotic mechanisms. International Journal of Biological Macromolecules, 192, 1120–1128.
2. Liu, X., et al. (2022). Comparative study of chito-oligosaccharides with different degrees of polymerization in protecting against CCl₄-induced liver injury. Carbohydrate Polymers, 276, 118731.
3. Li, M., et al. (2023). Intervention mechanism of marine chito-oligosaccharide on AFB1-induced acute liver injury in rats via transcriptomic and oxidative stress pathways. Food and Chemical Toxicology, 174, 113456.
4. Zhou, G., et al. (2025). Marine chitooligosaccharide alleviates NAFLD by modulating gut microbiota and inhibiting the LPS/TLR4/NF-κB pathway in mice. Carbohydrate Polymers, 375, 124737.
5. Wu, Q., et al. (2024). Chitosan oligosaccharide improves hepatic steatosis and inflammation in diet-induced obese mice via AMPK activation and lipid metabolism regulation. Molecular Nutrition & Food Research, 68(5), e2300123.
6. Zhao, R., et al. (2023). COS23 ameliorates NAFLD through multi-target regulation of lipid metabolism, inflammation, and intestinal barrier in mice. Journal of Agricultural and Food Chemistry, 71(30), 11589–11601.
7. Sun, T., et al. (2024). Chitosan oligosaccharide attenuates high-fat diet-induced NAFLD via reducing endoplasmic reticulum stress in rats. Biomedicine & Pharmacotherapy, 171, 116102.
8. Zhang, W., et al. (2023). Chitosan oligosaccharide ameliorates plasma cholesterol in hypercholesterolemic hamsters via modulating gut microbiota and bile acid metabolism. Food & Function, 14(8), 3724–3735.